Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou
about
michGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsFirst-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsFifty years of melphalan use in hematopoietic stem cell transplantationTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersSalvage second hematopoietic cell transplantation in myelomaEfficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma.A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myelomaConditioning regimens for hematopoietic cell transplantation: one size does not fit allArsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialHow we manage autologous stem cell transplantation for patients with multiple myelomaBusulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignanciesMucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment.Pharmacotherapy of multiple myeloma: an economic perspective.Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesIncreased intensity lymphodepletion and adoptive immunotherapy--how far can we go?Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.Cure of myeloma: hype or reality?Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspectsCurrent treatment options for myeloma.Role of allogeneic stem cell transplantation in multiple myeloma.The adverse prognostic impact of advanced age in multiple myeloma.Cure of multiple myeloma -- more hype, less reality.Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Pharmacotherapy of multiple myeloma.Treatment of multiple myeloma: an emphasis on new developments.Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma.Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeAutologous stem cell transplantation beyond 60 years of age.
P2860
Q24186266-FFE18096-3D6D-4360-B049-3BDC416D4374Q24197999-DB22349C-63FD-4D1D-A228-78E1A433AE50Q24200850-B7D69344-8704-4EB0-9A77-10DFE656EFF0Q26824498-07155A0F-3FD0-4977-B7A2-980A4A765C9BQ26851202-B4F0CEC0-5963-46BD-8817-E484FDFDE518Q30416452-3C1769D5-158B-44D3-9788-1E0C26072AD3Q33368609-E7B684B6-8D4F-4FA1-8C8E-D3EEA05255E7Q33369834-D474B293-12B6-4D4E-8417-4E646B22FE24Q33586505-428C8DE2-7F8D-4602-B986-407EE0836295Q33840656-F226DAA4-EA5C-4E32-A3CB-17E82126A410Q33917170-46709CF7-71DC-418C-91AC-90B87034F820Q33956059-AED9D91B-A29E-4058-A4DE-B6B3134D22DBQ34019581-8F11D3BA-0737-484D-8980-AD75C88DF60FQ34255145-E91AC058-2D87-45FC-A615-B3F8312B31E7Q34316924-C90AC5D7-032E-42F9-9B33-AF7BED64D70DQ34555067-3865BA71-5669-4B58-820B-205960D4FB91Q34568898-015942C3-620B-4698-9CD5-6E07CD29C4AAQ35079602-0B94947C-FBA8-4DE7-A9AE-3DA0DE4F1AADQ35095205-116F4DC9-B38E-4D63-BDD8-470E418822FEQ35219011-78F97564-144D-4F4A-AC8B-41904DF0350DQ35569350-8589FB56-1E33-4882-BE7F-C4D00417FFD8Q35594089-8118A56B-468E-42F8-AF2E-4578EA4A8F2AQ35597062-106B9918-630D-4005-BB0A-EAA2F3E9B801Q35638571-3A33E03B-CE61-43FE-A6FF-2C01D84C11ACQ35949091-7F2D3BE9-BC21-4CA3-98E8-3F0E13310F36Q36007610-8A6AC33B-2855-459D-8B9A-F009469DF2D9Q36083211-6BB9BBEE-7482-44A1-973F-A7E14D9BD9E1Q36163971-D5B993EF-6051-4258-89DD-F75FA79BD091Q36185617-86338603-78F7-4439-BBB2-A0C0D6875A60Q36194688-C262B23C-5403-4DF4-A2AC-E42B63039555Q36301128-4416D405-DD69-4D90-9F62-AA540BBA675AQ36373735-C9A965DA-0F58-4FE2-AE6E-973A3C99D422Q36407446-A86E83C6-E599-4D99-A882-B398A89E1F7DQ36429735-9F1EA3C7-8E98-48B4-BB2B-4FC94E8EAB7AQ36438215-CB2DFA90-A66E-49F9-92B8-3E062D33A37CQ36484561-2DFD75B1-2627-4A38-994F-6ACF4E5983DCQ36541807-260483C1-0F7A-4FE1-919E-8E23F6A271C5Q36573022-D690D553-35A4-446D-9CC6-AB752B5F25EDQ36575315-7EFE2B1D-95DB-4831-A400-8D48CD1E01FEQ36623644-26B9C9E2-EC3C-4DD6-BB57-97A873B605FE
P2860
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Comparison of 200 mg/m(2) melp ...... inal analysis of the Intergrou
@ast
Comparison of 200 mg/m(2) melp ...... inal analysis of the Intergrou
@en
type
label
Comparison of 200 mg/m(2) melp ...... inal analysis of the Intergrou
@ast
Comparison of 200 mg/m(2) melp ...... inal analysis of the Intergrou
@en
prefLabel
Comparison of 200 mg/m(2) melp ...... inal analysis of the Intergrou
@ast
Comparison of 200 mg/m(2) melp ...... inal analysis of the Intergrou
@en
P2093
P50
P356
P1433
P1476
Comparison of 200 mg/m(2) melp ...... inal analysis of the Intergrou
@en
P2093
Bernard Grosbois
Bernard Pignon
Bernard Rio
Chantal Doyen
Christian Berthou
Denis Caillot
Frédéric Maloisel
Gérald Marit
Intergroupe Francophone du Myélome
Jean-Jacques Sotto
P304
P356
10.1182/BLOOD.V99.3.731
P407
P577
2002-02-01T00:00:00Z